Walgreens is a dog…
In fact it’s been a dog for the better part of ten years now.
Walgreens Boots Alliance (WBA) – Monthly
In 2024, it earned itself a spot in the annual “Dogs of the Dow” portfolio. And it was, in large part, the reason that portfolio underperformed, losing 3% while the average as a whole was up nearly 13%!
The company lost over 64% on the year.
It’s lost just over 90% of its value since mid-2015.
The reasons for its tale of woe have been developing for a number of years and basically boil down to two factors: bad business decisions and struggles within the industry.
But it, like some other once-big names, has come to realize the error of its ways and is working to make a turn around.
Can they make it happen?
The Struggling Fall from Grace
The bad business decisions started all the way back in 2020 when Walgreens invested $6 billion for a majority ownership stake in a doctor-staffed clinic operator called VillageMD. The strategy followed an industry trend connecting medical service providers to pharmacies to create one-stop health solutions.
The plan was, “to open 500 to 700 “Village Medical at Walgreens” physician-led primary care clinics in more than 30 U.S. markets over five years.”
Business did not grow as projected. In the first three quarters of 2024, Walgreens’ operating loss grew to $13.1 billion.
A bigger issue, however, has been one that’s hitting the whole industry… getting paid.
In the drug business, the vast majority of prescriptions are paid for by insurance rather than customers directly. To that end, insurance companies hire “middlemen” known as pharmacy benefit managers (PBMs) who negotiate discounts and rebates from drug manufacturers and then set prices with pharmacies.
The PBM industry, dominated by three companies (all owned by insurance companies), exerts a huge amount of pressure on the pharmacy industry. And its been doing so for — wait for it — the past 10 years. About as long as Walgreens has been taking it on the chin.
According to reporting:
The reimbursement pressure that Walgreens experienced can be seen in its U.S. retail pharmacy gross margin, which fell from 28.2% in fiscal year 2014 to 17.9% in fiscal year 2024, ended in August.
That’s a problem.
Is a Turnaround in Progress?
In the face of talk that it could be bought out by a private equity company, Walgreens has been taking some serious steps to right this ship…
Plans to expand have been sharply curtailed and as newly-installed CEO Tim Wentworth informed the market:
“We believe in the future of these businesses and intend to remain an investor and partner [in VillageMD], but as part of our persistent focus on value creation for WBA, we are collaborating with leadership toward an endpoint to rapidly unlock liquidity and enhance optionality and position them for additional growth.”
Understanding the need to cut bad investments is always a good first sign of a serious turnaround. But in addition, the company is also slashing internally:
The company said last quarter that it surpassed its goal of reducing expenses by $1 billion and announced a plan to shutter nearly 14% of its store locations. It will close 1,200 of its 8,700 stores that it said are unprofitable over the next three years, including 500 stores in fiscal 2025, which ends in August.
Again, early signs are promising.
Last week, Walgreens reported its first quarter earnings (ending Nov 30) and gave Wall Street a pleasant surprise.
EPS came in at 51 cents vs. the street’s estimate of 37 cents. Revenue was a huge beat as well coming in at $39.46 billion vs. $37.36 billion.
That was the good news. The less than glowing news was that the company didn’t change their earnings outlook for 2025. Nor did they include sales guidance in their report. (Last October they guided at $147 billion to $151 billion for FY 2025.)
Still, you gotta take your good news where you can.
And the market did.
Walgreens Boots Alliance (WBA) – Daily
How they deal with the issue of reimbursement will remain to be seen.
But for now, WBA may be worth keeping an eye on.